Movatterモバイル変換


[0]ホーム

URL:


Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Free PMC article
Full text links

Actions

Share

.2022 Jan;37(1):40-50.
doi: 10.1007/s12291-020-00944-z. Epub 2021 Jan 6.

Development of Flow Injection Analysis Method for the Second-Tier Estimation of Succinylacetone in Dried Blood Spot of Newborn Screening

Affiliations

Development of Flow Injection Analysis Method for the Second-Tier Estimation of Succinylacetone in Dried Blood Spot of Newborn Screening

Bijo Varughese et al. Indian J Clin Biochem.2022 Jan.

Abstract

Tyrosinemia type 1 (TYR1) is a devastating aminoacidopathy, leading to mortality without medical intervention. Although, detection and quantification of tyrosine in dried blood spot (DBS) is possible, but being a non-specific marker for TYR1 and its frequent association with transient neonatal tyrosinemia limits its applicability. Despite, Succinylacetone (SUAC) being a pathognomonic marker for TYR1, but not often detectable by routine newborn screening (NBS). We envisaged to determine SUAC in DBS by an in-house flow injection analysis method on a liquid chromatography/tandem mass spectrometry (LC-MS/MS). Succinylacetone was eluted from the residual 3.2 mm DBS of primary NBS by an extraction solution containing acetonitrile-water-formic acid mixture containing stable-isotope labelled internal standard (IS) for SUAC and hydrazine. Detection and quantification was performed by the mass spectrometer using multiple reaction monitoring mode at m/z 155.1 → 109.1 for SUAC and m/z 160.1 → 114.1 for the SUAC IS. The assay was linear over a calibration range of 0.122-117.434 µmol/L. The Intra-day and Inter-day precision and accuracy for the assay was determined at two different levels of SUAC (2.542 µmol/L and 14.641 µmol/L), which showed a coefficient of variation of (6.91% and 12.65%) and (8.57% and 12.27%) respectively. The accuracy also ranged between 101.2 and 103.87%.This method provided the necessary sensitivity, precision, accuracy, recovery and linearity and hence, has the potential to reduce the false positive, false negative results which significantly minimise the cost involved in the screening and follow up of TYR1 patients.

Supplementary information: The online version of this article (10.1007/s12291-020-00944-z) contains supplementary material, which is available to authorized users.

Keywords: Fumarylacetoacetate hydrolase; Inborn errors of metabolism; Mass spectrometry; Newborn screening; Tyrosine; Tyrosinemia type 1.

© Association of Clinical Biochemists of India 2021.

PubMed Disclaimer

Conflict of interest statement

Conflict of interestThe authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Schematic workflow of sample preparation procedure
Fig. 2
Fig. 2
Chromatographic parameters
Fig. 3
Fig. 3
Representative chromatogram and mass spectra,a ESI mass spectrum of SUAC IS, mass transition 160.1 Da → 114.1 Da,b ESI mass spectrum of SUAC, mass transition 155.1 Da → 109.1 Da,c product ion mass spectrum
Fig. 4
Fig. 4
Calibration curve Conc. in µmol/L versus intensity (cps) for SUAC from blood spot calibrators
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Vernon HJ. Inborn errors of metabolism: advances in diagnosis and therapy. JAMA Pediatr. 2015;169:778–782. - PubMed
    1. Almannai M, Marom R, Sutton VR. Newborn screening: a review of history, recent advancements, and future perspectives in the era of next generation sequencing. Curr Opin Pediatr. 2016;28:694–699. - PubMed
    1. Levy HL, Shih VE, Madigan PM, MacCready RA. Transient tyrosinemia in full-term infants. JAMA. 1969;209:249–250. - PubMed
    1. Tanguay RM, Valet JP, Lescault A, Duband JL, Laberge C, Lettre F, et al. Different molecular basis for fumarylacetoacetate hydrolase deficiency in the two clinical forms of hereditary tyrosinemia (type I) Am J Hum Genet. 1990;47:308–316. - PMC - PubMed
    1. Mak CM, Lam C-W, Chim S, Siu T-S, Ng K-F, Tam S. Biochemical and molecular diagnosis of tyrosinemia type I with two novel FAH mutations in a Hong Kong chinese patient: recommendation for expanded newborn screening in Hong Kong. Clin Biochem. 2013;46:155–159. - PubMed

Related information

LinkOut - more resources

Full text links
Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.


[8]ページ先頭

©2009-2025 Movatter.jp